Hard to Treat Diseases, Incorporated Files U.S. Provisional Patent Application.

DELRAY BEACH, Fla. -- Hard to Treat Diseases, Incorporated (HTTD) (Pink Sheets: HTDS) Announces Filing of U.S. Provisional Application for Methods and Compositions for Treatment of Viral Infections.

HTTD is no longer a "one-drug company" that is reliant solely on the promotion of Tubercin(R).

The provisional application discloses the testing results of HTTD's proprietary formulation for the treatment of viral infections, which was recently filed on behalf of HTTD as a result of ongoing testing and research conducted on various compounds and substances that HTTD owns, controls or has the licensed rights to. Testing results could not be released until the provisional application was filed due to the confidential and sensitive nature of the information. Recently, the major focus of HTTD, its research team and patent attorneys has been on preparing and filing the provisional application.

Testing results to date have been finalized and incorporated in the provisional application. An overview of the results will be released in the very near future. The testing documents comprise a valuable asset that has been created for HTTD. This asset, along with the underlying testing documents, is confidential, not available to competitors, and HTTD has taken extraordinary steps to maintain its confidential nature and contents.

HTTD is no longer a "one-drug company" that is reliant solely on the promotion of Tubercin(R). In addition to our proprietary formulation and various compounds, referenced in the provisional application, HTTD also acquired and holds the worldwide (except Korea) marketing rights and license to manufacture, use, market, distribute and otherwise to commercialize Tubercin(R), which includes Tubercin(R)'s issued patents in the following countries:

Japanese patent:        issued  6/12/98
        United States patent:   issued  8/14/01
        European patent:        issued  8/13/03
        Canada patent:          issued  5/11/04

Mr. Colm J. King, CEO of HTTD, commented, "HTTD's value and goals have been strengthened with the provisional application. We will continue to aggressively advance the testing of Tubercin(R) in the U.S.; in addition to aggressively advance the testing of our proprietary formulation and other compounds and substances, contained in the provisional application, in the U.S.; and make strategic decisions with the goal of being involved in negotiations with major drug firms within 18 months."

Mr. King added, "Testing and evaluation results are an essential interim step in obtaining the FDA approval necessary to market a product. Our testing and research has been supervised and conducted in U.S. FDA approved laboratories by experienced medical and scientific professionals. HTTD will vigorously enforce its lawful rights, which includes defending its advantageous business relationships and negotiations that are instrumental in establishing a solid reputation and significant presence in our field and attaining the goals of benefiting patients and HTTD's shareholders."

HTTD is currently involved in litigation regarding the rights to Tubercin(R). Additional information and details regarding the litigation can be viewed on our website at: http://www.htdsotc.com

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.